|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
1993
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AX12
|
|
gptkbp:bioavailability
|
variable, decreases with increasing dose
|
|
gptkbp:brand
|
gptkb:Gralise
gptkb:Horizant
gptkb:Neurontin
|
|
gptkbp:chemicalFormula
|
C9H17NO2
structural analogue of GABA
|
|
gptkbp:contraindication
|
hypersensitivity to gabapentin
|
|
gptkbp:developedBy
|
gptkb:Parke-Davis
|
|
gptkbp:discoveredIn
|
1975
|
|
gptkbp:drugClass
|
gabapentinoid
|
|
gptkbp:drugInteraction
|
antacids reduce absorption
opioids increase CNS depression
|
|
gptkbp:eliminationHalfLife
|
5–7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstMarketedIn
|
1993
|
|
gptkbp:genericAvailable
|
true
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gabapentin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to α2δ subunit of voltage-gated calcium channels
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:molecularWeight
|
171.24 g/mol
|
|
gptkbp:notABarbiturate
|
true
|
|
gptkbp:notABenzodiazepine
|
true
|
|
gptkbp:notAnOpioid
|
true
|
|
gptkbp:notGABAergic
|
true
|
|
gptkbp:overdoseSymptoms
|
diarrhea
lethargy
drowsiness
slurred speech
double vision
|
|
gptkbp:patentExpired
|
true
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
potential risk
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
tremor
blurred vision
weight gain
drowsiness
ataxia
peripheral edema
|
|
gptkbp:usedFor
|
gptkb:restless_legs_syndrome
epilepsy
peripheral neuropathy
fibromyalgia
hot flashes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Anticonvulsants
|
|
gptkbp:bfsLayer
|
7
|